Try our Advanced Search for more refined results
Eli Lilly and Company Inter Partes Review
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Eli Lilly and Company
Patent Owner:
Tech Center:
-
Filed: April 11, 2022 00:00
Coverage
-
October 12, 2023
Eli Lilly Continues Migraine IP Wins Over Teva With PTAB Ax
Eli Lilly has persuaded the Patent Trial and Appeal Board to invalidate a Teva Pharmaceuticals patent for the migraine drug Ajovy, shortly after a Massachusetts federal judge overturned a related $176.5 million verdict against Eli Lilly.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
October 12, 2023